New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014–2017
Author:
Affiliation:
1. Drug Information Research Center, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
2. Medical Informatics and Biostatistics Department, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/17512433.2018.1526676
Reference29 articles.
1. European Union pharmacovigilance capabilities: potential for the new legislation
2. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making
3. Commission of the European Communities. Proposal for a directive of the European Parliament and of the Council amending, as regards pharmacovigilance, Directive 2001/83/EC on the community code relating to medicinal products for human use. COM(2008) 665 final [online] [cited 2018 Feb 23]. Available from: http://eur-lex.europa.eu/LexUriServ/%20LexUriServ.do?uri=COM:2008:0665:FIN:en:PDF
4. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works
5. The European Parliament and the Council of the European Union. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, regulation (EC) No 726/2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products [online] [cited 2018 Jan 24]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Understanding factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: a systematic review using the Theoretical Domains Framework;Research in Social and Administrative Pharmacy;2024-02
2. Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study;Drug Safety;2023-07-08
3. Why Product Information Should not be Set in Stone: Lessons from a Decade of Linezolid Therapeutic Drug Monitoring: An Opinion Paper;Therapeutic Drug Monitoring;2023-04
4. Lithium in Cancer Therapy: Friend or Foe?;Cancers;2023-02-08
5. Characteristics of drug safety alerts issued by the Spanish Medicines Agency;Frontiers in Pharmacology;2023-01-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3